BioprintingPatents

CELLINK granted Korean patent for ‘Clean Chamber’ bioprinting technology

The bioprinting company continues to strengthen protections of its unique bioprinting technologies

Swedish bioprinting company CELLINK has been granted a patent from the Korean Intellectual Property Office for its Clean Chamber Technology, which enables bioprinting in a clean, sterile environment. The patent in question protects the technology—which is used in the company’s flagship BIO X and INKREDIBLE+ bioprinters—within the Korean market.

The patented technology by CELLINK is crucial to enabling desktop bioprinting while also ensuring sterility throughout the process—an important factor when producing anything related to the medical field. The patent from the Korean Intellectual Property Office helps to strengthen the company’s protection of its unique bioprinting platform and takes the company a step closer to its goal of protecting core technologies in the bioprinting field.

CELLINK Patent Korea clean chamber

“We are extremely excited to have another granted patent for our revolutionary technology platform,” said Erik Gatenholm, CEO of CELLINK. “As a globally recognized leader in the field, it is essential for us to protect our technologies so that we can continue to offer the most innovative solutions to our customers and collaborators around the world. The Clean Chamber Technology is a unique, value adding feature that ensures that the printing environment inside the Bioprinter is kept sterile so that the user can reduce the risk of contaminations and protect the precious cells during the printing process.”

CELLINK also says it is currently conducting the patenting process in other countries to expand protections on its unique technology. In February 2019, the bioprinting company was also granted a patent for a method of printing tissue constructions by the Swedish Patent and Registration Office.

The Gothenburg-based company also holds a patent for its Cellulose Nanofibrillar Bioink material for bioprinting applications in cell culturing, tissue engineering and regenerative medicine.

Tags

Tess Boissonneault

Tess Boissonneault moved from her home of Montreal, Canada to the Netherlands in 2014 to pursue a master’s degree in Media Studies at the University of Amsterdam. It was during her time in Amsterdam that she became acquainted with 3D printing technology and began writing for a local additive manufacturing news platform. Now based in France, Tess has over two and a half years experience writing, editing and publishing additive manufacturing content with a particular interest in women working within the industry. She is an avid follower of the ever-evolving AM industry.

Related Articles

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!